Abstract
The latest illegal designer drug is benzylpiperazine with trade names such as “A2”, “Frenzy” and “Nemesis”, also commonly referred to as BZP (Fig. 14). It is a recreational drug with euphoric, stimulant properties. Its dopamine and serotonin agonist mechanism of action is believed to be similar to MDMA and the effects produced by BZP are comparable to those produced by amphetamine. Adverse effects have been reported following its use including psychosis, renal toxicity, and seizures [121]. It does not appear to be very addictive and no deaths have been reported following a sole ingestion of BZP, although there have been at least two deaths from the combination of BZP and MDMA. Its sale is banned in a few countries, including the United States, Australia, New Zealand and in parts of Europe. However, its legal status is currently less restrictive in some other countries such as Ireland and Canada, although investigations and regulations are pending under European Union laws. Originally synthesized as an antihelmintic and claimed to be similar in its effect to ecstasy it has been shown to result in tachycardia, hypertonia and even epileptic seizures.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wood DM, Dargan PI, Button J, Holt DW, Ovaska H, Ramsey J, et al. Collapse, reported seizure – and an unexpected pill. Lancet. 2007;369:1411–3.
White R, Standen O. Piperazine in the treatment of threadworms in children; report on a clinical trial. Br Med J. 1953;2:755–8.
Standen O. Activity of piperazine, in vitro, against Ascaris lumbricoides. Br Med J. 1955;2:20–2.
Campbell H, Cline W, Evans M, Lloyd J, Peck A. Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur J Clin Pharmacol. 1973;6:170–6.
Gee P, Fountain J. Party on BZP party pills in New Zealand. N Z Med J. 2007;120:u2422.
Alansari M, Hamilton D. Nephrotoxicity of BZP-based herbal party pills: a New Zealand case report. N Z Med J. 2006;119:U1959.
Baumann M, Clark R, Budzynski A, Partilla J, Blough B, Rothman R. Effects of “Legal X” piperazine analogs on dopamine and serotonin release in rat brain. Ann N Y Acad Sci. 2006;1025:189–97.
Tekes K, Tóthfalusi L, Malomvölgyi B, Hermán F, Magyar K. Studies on the biochemical mode of action of EGYT-475, a new antidepressant. Pol J Pharmacol Pharm. 2007;30:203–11.
Lyon R, Titeler M, McKenney J, Magee P, Glennon R. Synthesis and evaluation of phenyl- and benzylpiperazines as potential serotonergic agents. J Med Chem. 1986;29:630–4.
Brennan KA, Lake B, Hely L, H. S., Jones K, K., Gittings D, Colussi-Mas J, et al. N-Benzylpiperazine has characteristics of a drug of abuse. Behav Pharmacol. 2007;18:785–90.
Brennan K, Johnstone A, Fitzmaurice P, Lea R, Schenk S. Chronic benzylpiperazine (BZP) exposure produces behavioral sensitization and cross-sensitization to methamphetamine (MA). Drug Alcohol Depend. 2007;88:204–13.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2009 Springer Science + Business Media B.V.
About this chapter
Cite this chapter
Freye, E. (2009). Benzylpiperazine (BZP) as a Designer Drug. In: Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-2448-0_32
Download citation
DOI: https://doi.org/10.1007/978-90-481-2448-0_32
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-2447-3
Online ISBN: 978-90-481-2448-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)